NVC Share Price

Open 6.75 Change Price %
High 6.75 1 Day 0.18 2.76
Low 6.70 1 Week 0.00 0.00
Close 6.70 1 Month 0.00 0.00
Volume 1150 1 Year 0.00 0.00
52 Week High 0.65
52 Week Low 0.40
NVC Important Levels
Resistance 2 6.75
Resistance 1 6.73
Pivot 6.72
Support 1 6.67
Support 2 6.65
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
FO 0.07 0.00%
FO 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
VRS 0.04 100.00%
VRS 0.04 100.00%
GV 0.02 100.00%
GV 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
BVQ 0.02 100.00%
NAI 0.02 100.00%
NAI 0.02 100.00%
NAI 0.02 100.00%
More..
CVE Canada Top Losers Stocks
VEL 0.00 -100.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
SKK 0.12 -33.33%
More..

Neovasc Inc (CVE: NVC)

NVC Technical Analysis 2
As on 20th Jun 2014 NVC Share Price closed @ 6.70 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.67 & Sell for SHORT-TERM with Stoploss of 6.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVC Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NVC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.neovasc.com
NVC Address
NVC
13700 Mayfield Place
Suite 2135
Richmond, BC V6V 2E4
Canada
Phone: 604-270-4344
Fax: 604-270-4384
Interactive Technical Analysis Chart Neovasc Inc ( NVC CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neovasc Inc
NVC Business Profile
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Neovasc Reducer for the treatment of refractory angina; and Tiara technology in development for the transcatheter treatment of mitral valve disease. The company also develops and manufactures the PeriPatch, a line of biological tissue products for use in third-party medical products, including transcatheter heart valves. In addition, the company provides a range of custom Peripatch products to industry customers for incorporation into their own products; and consulting and original equipment manufacturing services to other medical device companies. Further, it offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.